These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 8833200)

  • 1. Bisphosphonates: a review of their pharmacokinetic properties.
    Lin JH
    Bone; 1996 Feb; 18(2):75-85. PubMed ID: 8833200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of alendronate: an overview.
    Lin JH; Russell G; Gertz B
    Int J Clin Pract Suppl; 1999 Apr; 101():18-26. PubMed ID: 12669737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal handling of alendronate in rats. An uncharacterized renal transport system.
    Lin JH; Chen IW; Deluna FA; Hichens M
    Drug Metab Dispos; 1992; 20(4):608-13. PubMed ID: 1356743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates: the first 40 years.
    Russell RG
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of alendronate sodium.
    Gertz BJ; Holland SD; Kline WF; Matuszewski BK; Porras AG
    Osteoporos Int; 1993; 3 Suppl 3():S13-6. PubMed ID: 8298197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates: from the laboratory to the clinic and back again.
    Russell RG; Rogers MJ
    Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition of tiludronate (Skelid) in animals.
    Davi H; Tronquet C; Caix J; Simiand J; Briot C; Berger Y; Thiercelin JF
    Xenobiotica; 1999 Oct; 29(10):1017-31. PubMed ID: 10574683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates in the treatment of osteoporosis.
    Bell NH; Johnson RH
    Endocrine; 1997 Apr; 6(2):203-6. PubMed ID: 9225137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates in bone diseases.
    Sparidans RW; Twiss IM; Talbot S
    Pharm World Sci; 1998 Oct; 20(5):206-13. PubMed ID: 9820883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals.
    Lin JH; Duggan DE; Chen IW; Ellsworth RL
    Drug Metab Dispos; 1991; 19(5):926-32. PubMed ID: 1686238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between the chemistry and biological activity of the bisphosphonates.
    Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
    Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uptake of alendronate by bone tissue in hypocalcemic and hypercalcemic rats.
    Lin JH; Chen IW; Deluna FA
    Drug Metab Dispos; 1993; 21(5):800-4. PubMed ID: 7902239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodistribution and plasma protein binding of zoledronic acid.
    Weiss HM; Pfaar U; Schweitzer A; Wiegand H; Skerjanec A; Schran H
    Drug Metab Dispos; 2008 Oct; 36(10):2043-9. PubMed ID: 18625688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preclinical toxicology of bisphosphonates].
    Mondelo N; Peluffo VA; Parma MD; Cointry GR; Capozza RF; Ferretti JL; Piccinni E; Montuori E
    Medicina (B Aires); 1997; 57 Suppl 1():93-100. PubMed ID: 9567361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates and cancer.
    Milner RJ; Farese J; Henry CJ; Selting K; Fan TM; de Lorimier LP
    J Vet Intern Med; 2004; 18(5):597-604. PubMed ID: 15515572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced Oral Delivery of Bisphosphonate by Novel Absorption Enhancers: Improvement of Intestinal Absorption of Alendronate by N-Acyl Amino Acids and N-Acyl Taurates and Their Absorption-Enhancing Mechanisms.
    Nakaya Y; Takaya M; Hinatsu Y; Alama T; Kusamori K; Katsumi H; Sakane T; Yamamoto A
    J Pharm Sci; 2016 Dec; 105(12):3680-3690. PubMed ID: 27771051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of alendronate.
    Porras AG; Holland SD; Gertz BJ
    Clin Pharmacokinet; 1999 May; 36(5):315-28. PubMed ID: 10384857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural requirements for bisphosphonate actions in vitro.
    van Beek E; Hoekstra M; van de Ruit M; Löwik C; Papapoulos S
    J Bone Miner Res; 1994 Dec; 9(12):1875-82. PubMed ID: 7872052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
    Azuma Y; Sato H; Oue Y; Okabe K; Ohta T; Tsuchimoto M; Kiyoki M
    Bone; 1995 Feb; 16(2):235-45. PubMed ID: 7756053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats.
    Lin JH; Chen IW; deLuna FA; Hichens M
    J Pharmacol Exp Ther; 1993 Nov; 267(2):670-5. PubMed ID: 8246140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.